10-K: Medtronic FY26 Earnings Show Strong Growth

Medtronic plc reported robust financial results for fiscal year 2026, driven by significant growth across its key business segments.

Summary

• Medtronic plc reported strong performance for fiscal year 2026, with total net sales reaching $36.36 billion, an 8% increase year-over-year.
• The Cardiovascular Portfolio led growth with $13.98 billion in net sales, up 12%, driven by strong performance in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic divisions.
• The Neuroscience Portfolio saw net sales of $10.29 billion, a 4% increase, with growth in Cranial & Spinal Technologies and Neuromodulation.
• The Medical Surgical Portfolio reported $8.82 billion in net sales, a 5% increase, with contributions from Surgical & Endoscopy and Acute Care & Monitoring.
• The Diabetes Business, now presented as 'Other operating segment', showed a 13% increase in net sales to $3.11 billion.
• Diluted earnings per share (EPS) on a GAAP basis was $3.73, and on a non-GAAP basis, it was $5.53.
• Free cash flow increased to $5.43 billion from $5.19 billion in the prior year.
• The company repurchased approximately 10 million shares in fiscal year 2026 under its $5.0 billion share repurchase program.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing as positive, reflecting solid revenue growth and improved free cash flow, although tempered by increased costs related to tariffs and ongoing litigation.

Positives

• Total net sales increased by 8% to $36.36 billion.
• Cardiovascular net sales grew 12% to $13.98 billion, with Cardiac Rhythm & Heart Failure up 17% and Structural Heart & Aortic up 7%.
• Neuroscience net sales increased 4% to $10.29 billion.
• Medical Surgical net sales increased 5% to $8.82 billion.
• Diabetes net sales increased 13% to $3.11 billion.
• Free cash flow improved to $5.43 billion.
• The company announced an increase in its quarterly cash dividend to $0.72 per share for fiscal year 2027.
• The company acquired CathWorks Ltd. and Scientia Vascular, and announced the pending acquisition of SPR Therapeutics, Inc., strengthening its product portfolio.
• The company's cybersecurity risk management program is based on the NIST Cyber Security Framework 2.0.
• Medtronic achieved 100% pay equity for gender and ethnically diverse employees in the U.S. and 99% globally for gender.

Negatives

• Cost of products sold as a percentage of net sales increased due to $185 million in increased tariffs and duties and $84 million in asset write-offs.
• Selling, general, and administrative expenses increased due to expenses supporting the impending separation of the Diabetes Business.
• The company experienced a net loss of $150 million related to an intercompany sale of intellectual property and establishment of a deferred tax asset.
• A net cost of $70 million was associated with the separation of the Diabetes Business.
• The company recognized $113 million in certain litigation charges.
• The company is involved in ongoing litigation, including significant hernia mesh lawsuits and antitrust litigation with Applied Medical, which could result in substantial damages.
• The company's Puerto Rico manufacturing site is involved in ongoing tax litigation with the IRS, with potential material adverse effects.
• The company experienced a $157 million charge related to a future minimum royalty payment obligation under a research and development funding arrangement.

Risks

• Continued global penetration of Micra transcatheter pacing portfolio and adoption of Aurora EV-ICD system.
• Market acceptance and reimbursement for the Symplicity Spyral renal denervation system.
• Potential impact of tariffs and duties on cost structure and financial performance, with an estimated pre-tax net tariff impact of $250 million in fiscal year 2027.
• Risks associated with the ongoing separation of the Diabetes Business, including potential delays and costs.
• Cybersecurity threats and the potential for breaches, including a recent incident where an unauthorized third party accessed data in certain IT systems.
• Intense competition in the medical device industry, rapid technological change, and regulatory approval delays.
• Supply chain disruptions, including potential shortages of components like semiconductors and resins.
• Changes in healthcare policy, reimbursement regulations, and cost-containment measures by governments and payors.
• Litigation, claims, investigations, and regulatory proceedings are inherently unpredictable and could materially adversely affect business operations.
• Changes in tax laws or exposure to additional income tax liabilities, including the ongoing U.S. tax litigation related to Puerto Rico manufacturing.
• Reliance on information technology systems and the risk of cyber-attacks or disruptions.
• Geopolitical events and conflicts that could disrupt global supply chains and increase costs.

Future Outlook

Medtronic anticipates continued growth driven by the global penetration of its Micra transcatheter pacing portfolio, adoption of its Aurora EV-ICD system, and market acceptance of its Symplicity Spyral renal denervation system. The company also expects to navigate potential impacts from tariffs and the ongoing separation of its Diabetes Business. Future product pipeline developments and regulatory approvals are key to sustained growth across its segments.

Management Comments

• Medtronic's mission to alleviate pain, restore health, and extend life empowers us to engineer the extraordinary and deliver better outcomes for our world.
• We are confident in our ability to maximize new technology, AI, and data and analytics to tailor therapies in real-time, facilitating remote monitoring and care delivery that conveniently manages conditions, and creates new standards of care.
• We believe that improving health for people from all walks of life depends on our ability to unleash the creative power of our global employees.

Industry Context

StockSavvy.ai notes that Medtronic's performance reflects broader trends in the medical technology sector, including the increasing adoption of minimally invasive procedures, the integration of AI and data analytics into healthcare solutions, and the ongoing consolidation within the industry. The company's strategic focus on innovation and expanding global reach positions it to capitalize on these trends.

Comparison to Industry Standards

• Medtronic's revenue growth of 8% in FY2026 generally aligns with or exceeds the growth rates of many large-cap medical device companies, though specific comparisons depend on individual company fiscal year-ends and product mix.
• The company's free cash flow generation of $5.43 billion is a strong indicator of operational efficiency, a metric that is closely watched across the healthcare sector.
• The company's investment in R&D, at $2.9 billion, represents approximately 8% of net sales, which is in line with industry benchmarks for innovation-driven medical technology firms.
• The company's dividend increase to $0.72 per share demonstrates a commitment to shareholder returns, a common practice among established players in the healthcare industry like Johnson & Johnson and Abbott Laboratories.

Management Changes

Corporate Governance

Legal Proceedings

• Colibri patent litigation: U.S. Court of Appeals for the Federal Circuit ruled in favor of Medtronic, reversing a jury verdict and vacating the infringement finding.
• Hernia Mesh Litigation: Approximately 10,350 plaintiffs have filed lawsuits alleging personal injury from hernia mesh products; coordinated proceedings are ongoing.
• Diabetes Pump Retainer Ring Litigation: Lawsuits alleging personal injury from Series 600 insulin pumps with defective retainer rings; MiniMed will be responsible for liabilities.
• Antitrust Matters (Applied Medical): Jury returned a verdict in favor of Applied Medical, awarding $382 million in damages (to be trebled); Medtronic is challenging the verdict and plans to appeal.
• Environmental Proceedings: Ongoing remediation actions at various sites, including Orrington, Maine, and a settlement approved for mercury contamination in the Penobscot River.
• Italian Payback Legislation: Company has an accrued liability for medical device expenditures exceeding regional ceilings, with ongoing discussions regarding applicability for years 2019 onwards.
• Mallinckrodt Bankruptcy Litigation: Trust claims Covidien spun off its pharmaceutical business to avoid opioid liability; case is proceeding to discovery.
• IRS Tax Litigation: Ongoing dispute regarding income allocation between Medtronic, Inc. and its Puerto Rico subsidiary for fiscal years 2005-2006 and subsequent years; case is before the Tax Court.

Related Party Transactions

• The company has entered into research and development funding arrangements with affiliates of Blackstone Life Sciences Advisors L.L.C., recognizing income and potential future milestone payments and royalties.
• The company's IPO of MiniMed Group, Inc. resulted in Medtronic retaining approximately 90.03% ownership, with financial results of MiniMed consolidated.

Stakeholder Impact

• Shareholders: The company's performance, dividend increases, and share repurchase program are positive for shareholders. However, ongoing litigation and tax disputes pose potential risks.
• Employees: The company emphasizes employee development, pay equity, and a commitment to inclusion. A recent cybersecurity incident may impact data privacy.
• Customers: The company's product innovation and global reach benefit customers. However, supply chain challenges and regulatory changes could impact product availability.
• Creditors: The company's strong liquidity and credit ratings provide a stable outlook for creditors.

Next Steps

• Complete the separation of the Diabetes Business within the next fiscal year.
• Integrate acquired companies CathWorks Ltd. and Scientia Vascular into existing portfolios.
• Close the pending acquisition of SPR Therapeutics, Inc. in the first half of fiscal year 2027.
• Continue to monitor and manage the impact of tariffs and geopolitical events on operations and supply chains.
• Address ongoing litigation, including the hernia mesh and antitrust cases, and the U.S. tax litigation.

Key Dates

Recommendation

Medtronic demonstrates strong operational performance with solid revenue growth and improved free cash flow, supported by strategic acquisitions and a commitment to shareholder returns. However, significant ongoing litigation, particularly the Applied Medical antitrust case with a substantial jury award, and the unresolved IRS tax dispute in Puerto Rico introduce considerable uncertainty and potential financial risk. While the company's core business remains robust, these legal and tax matters warrant a cautious 'hold' rating until their outcomes are more definitively resolved.

Keywords

Medtronic, Form 10-K, Annual Report, Medical Devices, Healthcare Technology, Cardiovascular, Neuroscience, Medical Surgical, Diabetes Business, Financial Results, SEC Filing